Skip to main content
Tiziana Life Sciences Ltd logo

Tiziana Life Sciences Ltd — Investor Relations & Filings

Ticker · TLSA ISIN · BMG889121031 LEI · 984500769407C5E46F42 US Professional, scientific and technical activities
Open in API
Filings indexed 460 across all filing types
Latest filing 2020-04-01 Report Publication Anno…
Country BM Bermuda
Listing US TLSA

About Tiziana Life Sciences Ltd

https://www.tizianalifesciences.com/

Tiziana Life Sciences Ltd. is a clinical-stage biotechnology company focused on developing innovative immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's core strategy involves utilizing alternative drug delivery routes, such as intranasal administration, to modulate the immune system. Its lead clinical candidate, foralumab (TZLS-401), is the only fully human anti-CD3 monoclonal antibody being investigated for neurological conditions. Foralumab is in clinical development for the treatment of Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS), Alzheimer's disease, Amyotrophic Lateral Sclerosis (ALS), and Multiple System Atrophy (MSA). The company's pipeline also includes an anti-IL-6 receptor monoclonal antibody (TZLS-501) for potential application in lung diseases.

Recent filings

Filing Released Lang Actions
CURRENT REPORT OF FOREIGN ISSUER
Report Publication Announcement Classification · 95% confidence The document is a Form 6-K, which is a Current Report of Foreign Issuer filed with the SEC. It discusses the company's reliance on an SEC order to delay the filing of its Annual Report on Form 20-F due to COVID-19 related disruptions. The document does not contain the Annual Report itself or detailed financial data, but rather an announcement explaining the delay and the impact of COVID-19 on the company. It also includes a forward-looking statements disclaimer and a signature from the CEO. Given the content and length (7039 characters), this is an announcement related to the timing and delay of a report, not the report itself. Therefore, it fits the category of Report Publication Announcement (RPA).
2020-04-01 English
TIZIANA LIFE SCIENCES PLC
Major Shareholding Notification
2020-03-17 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC. It references a Regulatory News Service (RNS) announcement about the closing of an offering and resulting total voting rights. The document itself is short (2923 characters) and primarily serves to furnish the RNS announcement as an exhibit. It does not contain detailed financial statements or substantive financial data. The content is consistent with a regulatory filing that provides an update or announcement rather than a full report. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous filings that do not fit other categories and includes Form 6-K filings.
2020-03-16 English
FORM 424B5
Capital/Financing Update Classification · 100% confidence The document is a Form 424B5 prospectus supplement filed pursuant to Rule 424(b)(5) under the Securities Act. It details an offering of American Depositary Shares (ADSs) by Tiziana Life Sciences plc, including pricing, underwriting discounts, use of proceeds, risk factors, and other offering-related information. The document is a prospectus supplement and accompanying prospectus, which are typical for capital raising activities. It is not an annual or quarterly report, audit report, earnings release, or any other type of financial or governance report. The presence of underwriting details, offering price, and use of proceeds clearly indicate this is a capital/financing update. Therefore, the correct classification is Capital/Financing Update (CAP). The document length and detail support a high confidence score.
2020-03-13 English
REPORT OF FOREIGN PRIVATE ISSUER
Capital/Financing Update Classification · 100% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC. It details an underwriting agreement for a public offering of American Depositary Shares, including terms of the offering, use of proceeds, and related exhibits such as the underwriting agreement and legal opinion. The document is an announcement of a capital raising event and financing activity. It is not a full annual or quarterly report, nor is it a transcript, audit, or governance document. The content fits the category of Capital/Financing Update, as it provides detailed information about a financing transaction. The document length is 4373 characters, which is sufficient to contain substantive information about the financing. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2020-03-13 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC. It references a Regulatory News Service (RNS) announcement about a follow-on offering raising $10 million. The document itself is short (2890 characters) and primarily furnishes the RNS announcement as an exhibit. It does not contain detailed financial statements or substantive financial data but rather provides an update on a financing event. According to the rules, such a document is best classified as a Regulatory Filing (RNS) because it is a regulatory announcement that does not fit into more specific categories like Capital/Financing Update (CAP) or Earnings Release (ER) due to its form and content. The document is not the actual RNS announcement but a filing that furnishes it, which aligns with the RNS category as a fallback for miscellaneous regulatory filings.
2020-03-12 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.